FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis

Lung Cancer

Volumn 87, Issue 1, 2015, Pages 1-7

  Jiang, Tao ^a   Gao, Guanghui ^a   Fan, Guoxin ^b   Li, Mu ^a   Zhou, Caicun ^a  

^a SHANGHAI PULMONARY HOSPITAL   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Amplification; Fibroblast growth factor receptor 1; Lung squamous cell carcinoma; Meta analysis; Prognosis; Systematic review

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COCHRANE LIBRARY; EMBASE; ETHNICITY; FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; SYSTEMATIC REVIEW; GENETICS; LUNG TUMOR; META ANALYSIS; MORTALITY; ODDS RATIO; PATHOLOGY; RISK; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; ODDS RATIO; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SMOKING;

EID: 84922269241     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.11.009     Document Type: Article

References (38)

1. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014, 64:252-271.
2. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
3. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
4. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
5. Hammerman P.S., Lawrence M.S., Voet D., Jing R., Cibulskis K., Sivachenko A., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
6. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18:2443-2451.
7. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
8. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
9. Zhang J., Zhang L., Su X., Li M., Xie L., Malchers F., et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 2012, 18:6658-6667.
10. Brooks A.N., Kilgour E., Smith P.D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18:1855-1862.
11. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
12. Marek L., Ware K.E., Fritzsche A., Hercule P., Helton W.R., Smith J.E., et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009, 75:196-207.
13. Wang Y., Cai Y., Ji J., Liu Z., Zhao C., Zhao Y., et al. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett 2014, 344:82-89.
14. Crickard K., Gross J.L., Crickard U., Yoonessi M., Lele S., Herblin W.F., et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 1994, 55:277-284.
15. Freier K., Schwaenen C., Sticht C., Flechtenmacher C., Muhling J., Hofele C., et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007, 43:60-66.
16. Tomlinson D.C., Lamont F.R., Shnyder S.D., Knowles M.A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69:4613-4620.
17. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31:1097-1104.
18. Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med 2014, 3:681-692.
19. Dutt A., Ramos A.H., Hammerman P.S., Mermel C., Cho J., Sharifnia T., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011, 6:e20351.
20. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2:62ra93.
21. Goke F., Franzen A., Menon R., Goltz D., Kirsten R., Boehm D., et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2012, 142:1020-1026.
22. Heist R.S., Mino-Kenudson M., Sequist L.V., Tammireddy S., Morrissey L., Christiani D.C., et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012, 7:1775-1780.
23. Kohler L.H., Mireskandari M., Knosel T., Altendorf-Hofmann A., Kunze A., Schmidt A., et al. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch 2012, 461:49-57.
24. Sasaki H., Shitara M., Yokota K., Hikosaka Y., Moriyama S., Yano M., et al. Increased FGFR1 copy number in lung squamous cell carcinomas. Mol Med Rep 2012, 5:725-728.
25. Schildhaus H.U., Heukamp L.C., Merkelbach-Bruse S., Riesner K., Schmitz K., Binot E., et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012, 25:1473-1480.
26. Craddock K.J., Ludkovski O., Sykes J., Shepherd F.A., Tsao M.S. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J Thorac Oncol 2013, 8:1371-1377.
27. Gadgeel S.M., Chen W., Cote M.L., Bollig-Fischer A., Land S., Schwartz A.G., et al. Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLOS ONE 2013, 8:e79820.
28. Kim H.R., Kim D.J., Kang D.R., Lee J.G., Lim S.M., Lee C.Y., et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013, 31:731-737.
29. Tran T.N., Selinger C.I., Kohonen-Corish M.R., McCaughan B.C., Kennedy C.W., O'Toole S.A., et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer 2013, 81:462-467.
30. Ren M., Hong M., Liu G., Wang H., Patel V., Biddinger P., et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep 2013, 29:2181-2190.
31. Cihoric N., Savic S., Schneider S., Ackermann I., Bichsel-Naef M., Schmid R.A., et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer 2014.
32. Boehm D., Vogel W., Franzen A., Schrock A., Bootz F., Heaseley L.E., et al. A new bright-field dual-colour chromogenic and silver in situ hybridization method for the detection of FGFR1 gene copy number status. Virchows Arch 2014, 464:547-551.
33. Guagnano V., Kauffmann A., Wohrle S., Stamm C., Ito M., Barys L., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012, 2:1118-1133.
34. Angevin E., Lopez-Martin J.A., Lin C.C., Gschwend J.E., Harzstark A., Castellano D., et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013, 19:1257-1268.
35. FGFR inhibitor works in multiple cancers. Cancer Discov 2014, 4:626.
36. Pardo O.E., Wellbrock C., Khanzada U.K., Aubert M., Arozarena I., Davidson S., et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006, 25:3078-3088.
37. Pardo O.E., Latigo J., Jeffery R.E., Nye E., Poulsom R., Spencer-Dene B., et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009, 69:8645-8651.
38. Wilbertz T., Wagner P., Petersen K., Stiedl A.C., Scheble V.J., Maier S., et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011, 24:944-953.